THE CLAIMS

1. A topical skin pharmaceutical composition, comprising an active ingredient capable of inhibiting tyrosine kinase and an excipient suitable for topical preparation,

wherein the active ingredient comprises Icotinib or a pharmaceutically acceptable salt thereof;

wherein the excipient comprises a dispersion medium, an emulsifier or one or more pharmaceutically acceptable excipients of the topical preparation;

wherein the concentration of the active ingredient is 0.3-5 wt%;

wherein the dispersion medium comprises a water soluble matrix, or an oily matrix; the concentration of the water soluble matrix is 40-100 wt%; and the concentration of the oily matrix is 0-25 wt%;

wherein the emulsifier comprises an anionic emulsifier or a nonionic emulsifier; and the concentration of the emulsifier is 0-23 wt%.

2. The pharmaceutical composition according to claim 1, wherein the active ingredient comprises Icotinib freebase, Icotinib hydrochloride, Icotinib maleate or Icotinib phosphate.

3. The pharmaceutical composition according to claim 1 or 2, wherein the concentration of the active ingredient is 0.9-4.3 wt%.

4. The pharmaceutical composition according to claim 1, wherein the water soluble matrix is selected from the group consisting of water, glycerin, gelatin, ethanol, polyethylene glycol, propylene glycol, DMSO, and a cellulose derivative;

wherein the concentration of the water soluble matrix is 65-85 wt%.

5. The pharmaceutical composition according to claim 1, wherein the oily matrix is selected from the group consisting of a hydrocarbon matrix, an oil matrix, a lipid matrix and a silicon oxide polymer;

wherein the hydrocarbon matrix is selected from the group consisting of hexadecanol, octadecanol and liquid paraffin; the oil matrix is selected from the group consisting of soybean oil, castor oil, glycerin mono-, di-stearate and petroleum jelly; the lipid matrix comprises lanolin or beeswax; wherein the silicon oxide polymer is a dimethylsiloxane polymer;

wherein the concentration of the oily matrix is 9-11 wt%.

6. The pharmaceutical composition according to claim 1, wherein the anionic emulsifier comprises a monovalent soap or a fatty alcohol sulfate; the nonionic emulsifier comprises a higher fatty acid polyol ester, a polyethylene glycol fatty acid ester or a polyoxyethylene ether derivative;

wherein the monovalent soap is sodium stearate; the fatty alcohol sulfate comprises sodium dodecyl sulfate or sodium cetyl sulfate; the higher fatty acid polyol ester is selected from the group consisting of hexadecanol, octadecanol, stearic acid monoglyceride, poloxamer, polysorbate-80, polysorbate-60, and polysorbate-85; the polyoxyethylene ether derivative is alkyl polyoxyethylene ether; the polyethylene glycol fatty acid ester comprises polyethylene glycol-7-stearate or polyethylene glycol glyceryl oleate;

wherein the concentration of the emulsifier is 10-15 wt%.

7. The pharmaceutical composition according to any one of claims 1-6, wherein the pharmaceutically acceptable excipient of the topical preparation is a suspending agent; a pH regulator, a preservative, or a transdermal enhancer;

wherein the concentration of the suspending agent is 0-8.5 wt%; the concentration of the pH regulator is 0-12.8 wt%; the concentration of the preservative is 0-0.3 wt%; and the concentration of the transdermal enhancer is 0-45 wt%.

8. The pharmaceutical composition according to claim 7, wherein the suspending agent is a polymer suspending agent;

wherein the polymer suspending agent is selected from the group consisting of carbomer, polyvinylpyrrolidone, glucan, sodium carboxymethylcellulose, hydroxypropyl methyl cellulose, and methyl cellulose;

wherein the concentration of the suspending agent is 0-0.1 wt%.

9. The pharmaceutical composition according to claim 7, wherein the pH regulator comprises an alkali, an acid or a buffer solution;

wherein the alkali is selected from the group consisting of sodium hydroxide, potassium hydroxide and ammonium hydroxide; the buffer solution comprises a buffer pair consisting of a weak alkali and a weak acid;

wherein the weak acid is selected from the group consisting of citric acid, potassium acid phthalate and acetic acid; and the weak alkali is selected from the group consisting of triethanolamine, diethanolamine, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium citrate and sodium acetate;

wherein the concentration of the pH regulator is 0.2-1.5 wt%.

10. The pharmaceutical composition according to claim 7, wherein the preservative is selected from the group consisting of p-hydroxybenzoic acid esters and sorbic acid and its salt;

wherein the preservative is selected from the group consisting of ethyl p-hydroxybenzoate, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, sorbic acid, potassium sorbate, chlorocresol and chlorobutanol.

11. The pharmaceutical composition according to claim 7, wherein the transdermal enhancer is selected from the group consisting of diethylene glycol monoethyl ether and caprylocaproyl macrogol-8 glycerides;

wherein the concentration of the transdermal enhancer is 15-30 wt%.

12. The pharmaceutical composition according to any one of claims 1-11, wherein the pharmaceutical composition is an ointment;

wherein the ointment is a cream.

13. The pharmaceutical composition according to any one of claims 1-11, wherein the pharmaceutical composition is a gel;

wherein the gel is a transparent gel.

14. Use of the pharmaceutical composition of any one of claims 1-13 for the preparation of medicines for the treatment of a non-malignant excessive hyperplasia disorder or tumor and complications thereof.

15. The use according to claim 14, wherein the non-malignant excessive hyperplasia disorder is skin benign hyperplasia.

16. The use according to claim 14 or 15, wherein the non-malignant excessive hyperplasia disorder is dermatosis.

17. The use according to claim 16, wherein the dermatosis comprises psoriasis, scleroderma, or dermatosis caused by diabetes.

18. The use according to claim 16 or 17, wherein the dermatosis is psoriasis.

19. The use according to claim 14, wherein the tumor and complications thereof are dermatoma and its complications.